Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 34Gastrointestinal 28Thoracic 26Other hematologic neoplasm 23Genitourinary 20Head & Neck 16Other solid neoplasm 14Gynecologic 12Tumor-Agnostic 9Lymphoid 8Dermatologic 7CNS 6Plasma cell 5Sarcoma 3Other 2Myeloid 2Other neoplasm 1Endocrine 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Practice Guidelines as Topic × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡